A Systematic Review and Meta-Analysis of Immune-Related Adverse Events of Anti-PD-1 Drugs in Randomized Controlled

Yukun Wang1, Dejiu Kong1, Chaokun Wang1

  • 1Henan Key Laboratory of Cancer Epigenetics; Cancer Institute, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.

Abstract

Insights

Anti-programmed cell death 1 (PD-1) drugs significantly increase immune-related adverse events compared to control treatments. The risk of hyperthyroidism is also elevated, with similar event rates between pembrolizumab and nivolumab.

Area of Science:

  • Immunology
  • Oncology
  • Clinical Pharmacology

Background:

  • Immune-related adverse events (irAEs) are common with immune checkpoint inhibitors.
  • Understanding the specific irAEs associated with anti-programmed cell death 1 (PD-1) therapies is crucial for patient management.

Purpose of the Study:

  • To evaluate the incidence of irAEs in clinical trials of anti-PD-1 drugs versus control treatments.
  • To compare irAE occurrence between different anti-PD-1 agents, specifically nivolumab and pembrolizumab.

Main Methods:

  • Systematic review and meta-analysis of randomized controlled trials (RCTs).
  • Data sourced from PubMed, Embase, Cochrane Library, and clinicaltrials.gov.
  • Included RCTs comparing anti-PD-1 drugs with chemotherapy, targeted drugs, or placebo, published up to March 2019.

Main Results:

  • Eighteen RCTs involving 12 nivolumab and 6 pembrolizumab trials were analyzed.
  • Anti-PD-1 therapy significantly increased the risk of any irAE (RR, 2.65; P < 0.00001) compared to controls.
  • Increased risks were observed for pneumonitis, colitis, hypophysitis, hypothyroidism, hyperthyroidism, rash, pruritus, and hepatitis. The risk of hyperthyroidism was notably increased.
  • The incidence of irAEs was similar between pembrolizumab and nivolumab (P = 0.14).

Conclusions:

  • Anti-PD-1 drugs substantially elevate the risk of irAEs, including hyperthyroidism.
  • Nivolumab and pembrolizumab demonstrate comparable safety profiles regarding the overall risk of irAEs.